Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Portuguese researchers lead international consortium to develop novel clinical drug

30.10.2008
IMM leads first Portuguese coordination of FP-7 Marie-Curie Action IAPP (Industry-Academia Partnerships and Pathways) in partnership with the biotech company BIOALVO.

A five-partner European consortium coordinated by Portuguese researchers from the Instituto de Medicina Molecular (IMM) in Lisbon will perform the industrial development of a novel pharmaceutical drug. This novel drug has analgesic properties and has potential therapeutic application in the fight against neurodegenerative diseases such as Alzheimer’s or Parkinson’s diseases.

The compound (BLV200704) was conceived by Miguel Castanho’s research team, who is an IMM researcher, and was then licensed to the biotech company BIOALVO, which collaborated in subsequent stages of development of the drug.

The first steps of the research that lead to the development of BLV200704 resulted from collaboration between Miguel Castanho’s and Isaura Tavares’ research teams (IMM and Faculdade de Medicina/IBMC, Oporto University, Portugal, respectively) and counted on BIOALVO partnership in a latter stage of development.

The industrial development of the drug by a consortium of the Portuguese teams – IMM and BIOALVO - and two other from Spain and Germany is now approved by Marie-Curie IAPP Action (Industry-Academia Partnerships and Pathways – IAPP **), will involve approximately 600.000,00 Euros and is coordinated by Miguel Castanho at IMM, Lisbon.

The project, called PEP2BRAIN, will consolidate the pharmacological development of BLV200704 and its potential derivatives.

This is the first Portuguese partnership successfully approved by the demanding and highly competitive IAPP Marie-Curie Action from the European Seventh Framework Programme (FP-7). Marie-Curie Actions from the FP-7 “People” Programme, and in particular IAPP, seek the support of innovative partnerships between public research centers and private institutions, namely small and medium enterprises, which have the ultimate goal of developing novel products and solutions.

“The EU approval of this project shows the emergence of an economy of innovation in Portugal and reflects the growth of scientific knowledge and a novel attitude of Portuguese researchers”, says Miguel Castanho, researcher at IMM and coordinator of the present consortium. “In our specific case, the partnership with industry, namely with BIOALVO, has been highly productive and reveals the potential to develop novel products capable of contributing to the enhancement of the life standards, especially of those who suffer from disease. This potential has been recognized by the panel of experts that recommended the approval of our application to EU’s IAPP Action.”

Patrícia Calado, BIOALVO’s Drug Discovery and Development Director, said: “It is very rewarding for BIOALVO to be the first Portuguese company to successfully accomplish the evaluation step of an FP7 IAPP proposal. The achievement of this milestone reinforces the value of establishing high quality partnerships between industry and academia. The work developed in collaboration with the group of Prof. Miguel Castanho is a combined effort acknowledged by the European Commission as a high-quality translational research program which is now successfully moving into advanced phases of drug development”.

* Members of the consortium: Instituto de Medicina Molecular (Portugal), BIOALVO SA (Portugal), University of Girona (Spain), Synovo GmbH (Germany) and University Eberhard Karls, Tübingen (Germany).

Marta Agostinho | alfa
Further information:
http://cordis.europa.eu/fp7/people/industry-academia_en.html
http://www.imm.ul.pt

Further reports about: Alzheimer BIOALVO CONSORTIUM Development Drug FP-7 IAPP IMM Lead Marie-Curie Molecular Parkinson develop neurodegenerative disease novel

More articles from Life Sciences:

nachricht For a chimpanzee, one good turn deserves another
27.06.2017 | Max-Planck-Institut für Mathematik in den Naturwissenschaften (MPIMIS)

nachricht New method to rapidly map the 'social networks' of proteins
27.06.2017 | Salk Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Touch Displays WAY-AX and WAY-DX by WayCon

27.06.2017 | Power and Electrical Engineering

Drones that drive

27.06.2017 | Information Technology

Ultra-compact phase modulators based on graphene plasmons

27.06.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>